Emergent BioSolutions announced today it has named former Bausch + Lomb CEO Joseph Papa to the top job as the company, which makes the opioid overdose reversal drug Narcan, aims to return to revenue growth.
Tag Archive for: Bausch + Lomb
The announcement comes after the company struck a $1.75 billion deal with Swiss drugmaker Novartis late last month to buy several eye-care products including anti-inflammation eye drop Xiidra.
Acquisition of the anti-inflammation eye drop Xiidra will mark the first big deal by CEO Brent Saunders since he returned to the company in March. The agreement also includes potential milestone payments of up to $750 million to Novartis.
The regulator’s approval makes Miebo the first DED treatment that directly addresses tear evaporation. The drug is expected to hit U.S. markets in the second half of 2023.
Bausch + Lomb Corp. on Wednesday named Brent Saunders, the former chief executive officer of Allergan, as its CEO and chairman of board, marking his return to the Canadian eye-care company after nearly a decade.
